Literature DB >> 23222459

Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy.

Edward J Wladis1, Naomi S Falk, Bibiana V Iglesias, Paul M Beer, Edmund J Gosselin.   

Abstract

PURPOSE: Previous investigations have explored molecular differences between proliferative vitreoretinopathy and primary retinal detachment. An exploration of a greater number of molecules might provide novel insight into the biology of this disorder and identify potential therapeutic targets.
METHODS: Vitreous specimens were obtained from patients with epiretinal membranes or macular puckers (n = 15), patients with a primary retinal detachment without proliferative vitreoretinopathy (n = 15), and patients with retinal detachments and proliferative vitreoretinopathy (n = 15). A multiplex assay was performed to calculate the concentrations of 48 different cytokines and chemokines, and statistical analyses were performed to identify differences between the groups.
RESULTS: Of the 48 molecules that were studied, we identified 10 that were statistically significantly different in cases of proliferative vitreoretinopathy, including interleukins 4, 5, 6, and 15; granulocyte-macrophage colony-stimulating factors; stem cell factor; stem cell growth factor; macrophage inflammatory protein 1α; and interferon γ-induced protein 10.
CONCLUSION: Proliferative vitreoretinopathy represents a highly ordered molecular process that involves discrete changes in the concentrations of specific cytokines and chemokines. These molecules may represent novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23222459     DOI: 10.1097/IAE.0b013e31826d350a

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy.

Authors:  C Symeonidis; S Androudi; I Georgalas; A Tzamalis; N Chalvatzis; T Rotsos; E Souliou; E Diza; S A Dimitrakos
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

2.  Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy.

Authors:  Shikun He; Ernesto Barron; Keijiro Ishikawa; Hossein Nazari Khanamiri; Chris Spee; Peng Zhou; Satoru Kase; Zhuoshi Wang; Laurie Diane Dustin; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

3.  Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target.

Authors:  C Nathaniel Roybal; Gabriel Velez; Marcus A Toral; Stephen H Tsang; Alexander G Bassuk; Vinit B Mahajan
Journal:  Am J Ophthalmol       Date:  2017-12-13       Impact factor: 5.258

4.  Arsenic trioxide inhibits proliferation of retinal pigment epithelium by downregulating expression of extracellular matrix and p27.

Authors:  Ying Su; Feng Wang; Qi Hu; Yixin Qu; Ying Han
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

5.  Rapid monocyte infiltration following retinal detachment is dependent on non-canonical IL6 signaling through gp130.

Authors:  Xinlei Wang; Eric B Miller; Mayank Goswami; Pengfei Zhang; Kaitryn E Ronning; Sarah J Karlen; Robert J Zawadzki; Edward N Pugh; Marie E Burns
Journal:  J Neuroinflammation       Date:  2017-06-23       Impact factor: 8.322

6.  Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous.

Authors:  Yashavanthi Mysore; Eva M Del Amo; Sirpa Loukovaara; Marja Hagström; Arto Urtti; Anu Kauppinen
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

7.  Position of macula lutea and presence of proliferative vitreoretinopathy affect vitreous cytokine expression in rhegmatogenous retinal detachment.

Authors:  Anikó Balogh; Tibor Milibák; Viktória Szabó; Zoltán Zsolt Nagy; Miklós D Resch
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.